AssetMark Inc’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

AssetMark Inc’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-125	Closed	-$3K	–	1600
2021 Q1	$3K	Buy	125 +20	+19%	+$511	﹤0.01%	1146
2020 Q4	$2K	Buy	105 +9	+9%	+$198	﹤0.01%	1265
2020 Q3	$2K	Hold	96	–	–	﹤0.01%	1184
2020 Q2	$2K	Hold	96	–	–	﹤0.01%	1143
2020 Q1	$2K	Buy	96 +27	+39%	+$525	﹤0.01%	1222
2019 Q4	$2K	Hold	69	–	–	﹤0.01%	1276
2019 Q3	$1K	Buy	+69	New	+$986	﹤0.01%	1287

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AssetMark Inc's DRNA Position: Q2 2021 in Review

AssetMark Inc sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 125 shares — an estimated $3K sold.

AssetMark Inc first reported a position in DRNA in Q3 2019 and held it in 7 quarters. The position peaked at $3K in Q1 2021. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

AssetMark Inc reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
AssetMark Inc sold 125 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $3K.
AssetMark Inc first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and held it in 7 quarters.
AssetMark Inc's Dicerna Pharmaceuticals, Inc. position peaked at $3K in Q1 2021.
203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on AssetMark Inc's 13F filing for Q2 2021, filed 16 Aug 2021.